Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Everolimus

FDA-approved product (tablet, oral), marketed as Afinitor, Afinitor Disperz, Everolimus and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Everolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Anaplastic astrocytoma
  • Angiomyolipoma
  • Astrocytoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Clear cell renal carcinoma
  • Hamartoma
  • Kidney Angiomyolipoma
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Pancreatic neuroendocrine tumor
  • and 5 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Everolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Everolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

    NCT01188889 · start 2013-09

    Registered record
    Registry ID
    NCT01188889
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    RAD001; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionRAD001; Imatinib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

    NCT01923740 · start 2013-07

    Registered record
    Registry ID
    NCT01923740
    Conditions
    Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis
    Interventions
    XIENCE V EECSS; Absorb BVS System
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-07
    Completion
    2019-03-07
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis
    InterventionXIENCE V EECSS; Absorb BVS System
    PhaseNot applicable
    Registry statusCompleted

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

    NCT01665053 · start 2012-11

    Registered record
    Registry ID
    NCT01665053
    Conditions
    Coronary Artery Disease
    Interventions
    PROMUS Element Plus; SYNERGY
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2018-12-22
    Enrolment
    1,684

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPROMUS Element Plus; SYNERGY
    PhasePhase 3
    Registry statusCompleted

  • A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    NCT01771458 · start 2012-10

    Registered record
    Registry ID
    NCT01771458
    Conditions
    Reccurent/Metastatic Solid Tumor Disease
    Interventions
    Targeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus; Targeted therapy based on molecular profiling : Vemurafenib; Targeted therapy based on molecular profiling : Sorafenib; Targeted therapy based on molecular profiling : Erlotinib; Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Targeted therapy based on molecular profiling : Dasatinib; Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Targeted therapy based on molecular profiling : Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-12
    Enrolment
    742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReccurent/Metastatic Solid Tumor Disease
    InterventionTargeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus +7 more
    PhasePhase 2
    Registry statusCompleted

  • Short and Optimal Duration of Dual Antiplatelet Therapy Study

    NCT01659034 · start 2012-09

    Registered record
    Registry ID
    NCT01659034
    Conditions
    Coronary Artery Disease
    Interventions
    Thienopyridine for 3 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-12
    Enrolment
    1,525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionThienopyridine for 3 months
    PhasePhase 4
    Registry statusCompleted

  • PROMUS Element Plus US Post-Approval Study

    NCT01589978 · start 2012-05

    Registered record
    Registry ID
    NCT01589978
    Conditions
    Coronary Artery Disease
    Interventions
    PROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-05
    Completion
    2018-06
    Enrolment
    2,681

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonist
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

    NCT01515228 · start 2012-01

    Registered record
    Registry ID
    NCT01515228
    Conditions
    Coronary Artery Disease
    Interventions
    Xience Prime; Cilotax stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2015-01
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionXience Prime; Cilotax stent
    PhasePhase 4
    Registry statusCompleted

  • ABSORB PHYSIOLOGY Clinical Investigation

    NCT01308346 · start 2011-11

    Registered record
    Registry ID
    NCT01308346
    Conditions
    Coronary Artery Disease
    Interventions
    Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS); XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2013-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionBioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS); XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
    PhaseNot applicable
    Registry statusTerminated

  • EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

    NCT01435031 · start 2011-09

    Registered record
    Registry ID
    NCT01435031
    Conditions
    Coronary Artery Disease (CAD); Chronic Total Occlusion (CTO)
    Interventions
    CTO Treatment Device
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-09
    Completion
    2017-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD); Chronic Total Occlusion (CTO)
    InterventionCTO Treatment Device
    PhaseNot applicable
    Registry statusCompleted

  • Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease

    NCT01443754 · start 2011-09

    Registered record
    Registry ID
    NCT01443754
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    LIMA-LAD surgical revascularization; PCI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionLIMA-LAD surgical revascularization; PCI
    PhaseNot recorded
    Registry statusTerminated

  • Drug Eluting Stents In The Critically Ischemic Lower Leg 2

    NCT01442636 · start 2011-07

    Registered record
    Registry ID
    NCT01442636
    Conditions
    Peripheral Arterial Disease
    Interventions
    stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Arterial Disease
    Interventionstent
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

    NCT01332279 · start 2011-04

    Registered record
    Registry ID
    NCT01332279
    Conditions
    Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer
    Interventions
    everolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis; immunohistochemistry staining method; polyacrylamide gel electrophoresis; pharmacological study; external beam radiation therapy; microarray analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx +7 more
    Interventioneverolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis +5 more
    PhasePhase 1
    Registry statusWithdrawn

  • Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization

    NCT01342822 · start 2010-10

    Registered record
    Registry ID
    NCT01342822
    Conditions
    Ischemic Heart Disease; Coronary Artery Stenosis
    Interventions
    Angioplasty (PROMUS Element™, and Xience™ Prime stent)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-10
    Completion
    2014-03
    Enrolment
    2,980

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Heart Disease; Coronary Artery Stenosis
    InterventionAngioplasty (PROMUS Element™, and Xience™ Prime stent)
    PhaseNot recorded
    Registry statusUnknown

  • Everolimus Versus Placebo in Head and Neck Cancer

    NCT01111058 · start 2010-04

    Registered record
    Registry ID
    NCT01111058
    Conditions
    Head and Neck Cancer
    Interventions
    Everolimus (RAD 001); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-04
    Completion
    2018-10
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionEverolimus (RAD 001); Placebo
    PhasePhase 2
    Registry statusTerminated